Skip to main content
TipRanks
Go Ultimate75% OFF

Mesoblast Limited (LWB) AI Stock Analysis

4 Followers
DE:LWB

Mesoblast Limited

(Frankfurt:LWB)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Ryoncil revenue growthRyoncil has established an initial commercial revenue base and is expected to grow substantially in its first full fiscal year. This demonstrates early product adoption and provides Mesoblast with a recurring foundation from which broader payer access, center onboarding, and label expansion can support durable growth.
Negative Factors
Persistent losses and cash burnMesoblast remains loss-making and consumes cash despite the sharp increase in revenue. Continued negative operating and free cash flow means commercial growth has not yet funded the business, leaving profitability dependent on further revenue scaling, expense discipline, and successful execution of development programs.

Mesoblast Limited (LWB) vs. iShares MSCI Germany ETF (EWG)

-20%-10%0%10%20%30%40%50%DE:LWB-4.10%EWG+10.70%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 1.48B
Dividend Yield
―
Average Volume (3M)
2,078
Price to Earnings (P/E)
-29.4
Beta (1Y)
0.98
Revenue Growth
553.65%
EPS Growth
51.03%
Country
Germany
Employees
108
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Mesoblast Limited Business Overview & Revenue Model

Company Description

Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerlan...

Mesoblast Limited Earnings Call Summary

Earnings Call Date:Feb 27, 2026(Q2-2026)|% Change Since:-9.30%|Next Earnings Date:May 29, 2024
Earnings Call SentimentPositive

The call communicated strong commercial momentum from the Ryoncil launch (USD 49M H1 revenue), industry-leading gross margins (93%), broad payer coverage, rapid center onboarding and multiple near-term regulatory and clinical milestones (Revascor BLA next quarter; back pain enrollment completion and 2027 BLA). The company also strengthened its balance sheet with USD 130M cash and a USD 125M credit facility. Offsetting risks include a sharp increase in R&D and SG&A spending, reliance on Ryoncil for most revenues, ongoing manufacturing/CMC items ahead of filings, and near-term cash usage (USD 30.3M H1) with a tranche deadline in June 2026. Overall, the positive operational, clinical and financial developments materially outweigh the execution and expense risks.

Positive Updates

Successful Ryoncil Launch and Revenue
Ryoncil launched April 2025 and generated net product revenues of USD 49.0M in H1 FY'26, driving total company revenues of USD 51.3M (Ryoncil ≈95.5% of revenues). Company projects full-year Ryoncil net revenues of USD 110M–120M for FY'26 (implying substantial H2 growth vs H1).

Negative Updates

Substantial Increase in R&D Spend
R&D expenses rose to USD 46.2M versus USD 5.1M reported prior-year (an increase of ~806%), though prior-year figures were skewed by a USD 23M inventory provision reversal (normalized prior-year R&D ≈USD 18.1M). Against the normalized base this represents a ~156% increase, driven by clinical programs (GVHD, back pain, LVAD) and BLA/manufacturing work.

Company Guidance

Management reiterated FY2026 guidance and laid out key metrics: H1 revenues were $51.3M with Ryoncil net product revenues of $49M and a 93% gross margin (gross margin excl. amortization ~$44.2M); direct selling costs $7.7M, R&D $46.2M, SG&A $28.5M, net loss $40.2M, and H1 operating cash use $30.3M. Cash was $130M at Dec 31 and Mesoblast has a $125M credit facility (first tranche $75M drawn, $50M available through June 2026); the subordinated royalty facility is expected to be fully repaid by mid‑2026 and operating cash use is expected to decline in H2. For Ryoncil they expect full‑year net revenues of $110–120M, target ~20% pediatric penetration by year‑end (based on a ~375‑patient base and a 40% peak‑share assumption), have onboarded 49 centers (30 with formulary listings; 13 using Optum Frontier), secured coverage for >280M lives with Medicaid in all states and J‑code J3402 effective Oct 1, and plan label expansion into adults (market ~3x pediatric). Pipeline milestones include rexlemestrocel‑L (404‑patient Phase III completed; confirmatory 300‑patient trial enrolling with enrollment expected by Mar/Apr and a 2027 data/BLA timeline) and Revascor (LVAD II: 159‑patient 2:1 RCT plus supportive 30‑patient study showing ~5‑fold reduction in major bleeding through 12 months and survival benefit) with a BLA filing for full approval planned next quarter.

Mesoblast Limited Risk Analysis

Mesoblast Limited disclosed 80 risk factors in its most recent earnings report. Mesoblast Limited reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Concentrated share ownership and Australian takeover laws may discourage takeover offers and limit shareholder opportunities.Q2, 2026
2.Post-approval safety findings, real-world evidence, or failures in pharmacovigilance could materially and adversely affect the continued commercialization of Ryoncil.Q2, 2026
3.Our ability to commercialize Ryoncil continues to depend on complex reimbursement, coding, and site-of-care dynamics, which may limit continued adoption even where clinical demand exists.Q2, 2026

Mesoblast Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:LWB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:TRPAU:TRP47NeutralAUD 5.86M-1.24-52.04%―32.22%-26.53%
AU:OCCAU:OCC44NeutralAUD 152.54M-10.47-36.83%―51.07%-47.63%
AU:CYPAU:CYP43NeutralAUD 4.35M-0.36-617.89%――13.67%
AU:1AIAU:1AI40UnderperformAUD 18.25M-5.14-132.20%――-200.00%
AU:CMBAU:CMB39UnderperformAUD 10.60M-1.43-247.44%―-4.24%33.39%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:LWBAU:CYPAU:1AIAU:OCCAU:TRPAU:CMBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:LWB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:LWBMesoblast Limited1.17-0.03-2.50%
AU:CYPCynata Therapeutics Limited0.01-0.22-94.47%
AU:1AILiving Cell Technologies Ltd.0.010.000.00%
AU:OCCOrthocell Ltd0.56-0.42-42.86%
AU:TRPTissue Repair Ltd0.11-0.18-62.07%
AU:CMBRegeneus Ltd.0.36-0.15-29.41%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.